GeorgiaTuberculosis profile
Population  2017 3.9 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.21 (0.16–0.27) 5.3 (4.1–6.8)
Mortality (HIV+TB only) 0.013 (<0.01–0.017) 0.34 (0.25–0.44)
Incidence  (includes HIV+TB) 3.4 (2.8–3.9) 86 (72–101)
Incidence (HIV+TB only) 0.059 (0.049–0.07) 1.5 (1.2–1.8)
Incidence (MDR/RR-TB)** 0.73 (0.55–0.94) 19 (14–24)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.18 (0.17–0.19) 1 (0.92–1.1) 1.2 (1.1–1.3)
Males 0.2 (0.19–0.21) 2 (1.7–2.2) 2.2 (1.9–2.5)
Total 0.38 (0.36–0.4) 3 (2.5–3.4) 3.4 (2.8–3.9)
TB case notifications, 2017  
Total cases notified 2 927
Total new and relapse 2 597
          - % tested with rapid diagnostics at time of diagnosis 81%
          - % with known HIV status 94%
          - % pulmonary 80%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 77% (66–93)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.07 (0.05–0.09)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 43 2%
          - on antiretroviral therapy 43 100%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  400
(360–440)
Estimated % of TB cases with MDR/RR-TB 11% (9.7–13) 30% (26–34)  
% notified tested for rifampicin resistance 71% 74% 2 111
MDR/RR-TB cases tested for resistance to second-line drugs   296
Laboratory-confirmed cases MDR/RR-TB: 339, XDR-TB: 49
Patients started on treatment **** MDR/RR-TB: 343, XDR-TB: 47
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 83% 2 715
Previously treated cases, excluding relapse, registered in 2016 58% 226
HIV-positive TB cases registered in 2016 57% 44
MDR/RR-TB cases started on second-line treatment in 2015 56% 412
XDR-TB cases started on second-line treatment in 2015 56% 62
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 20%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
21% (20–23)
TB financing, 2018  
National TB budget (US$ millions) 19
Funding source: 32% domestic, 40% international, 27% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-10-19 Data: www.who.int/tb/data